Splenda® helps people reduce added sugars while keeping the sweetness and enjoyment they expect. A trusted brand, backed by evidence, built to support the conversations you have every day.
Patients asking about a recent sweetener headline? See how the weight of the evidence answers it in Common Questions.
A full non‑nutritive sweetener (NNS) portfolio including sucralose, stevia, and monk fruit.
See the benefits →Everyday foods and beverages are full of added sugars. Splenda® gives patients a realistic way to cut added sugars while keeping the sweetness they enjoy.
Patient resources →The patients you counsel every day: diabetes and prediabetes, overweight and obesity, weight management, and lower‑sugar lifestyles.
Why it matters →Every sweetener in the Splenda® family holds US regulatory clearance1,5,6,7,8 and is supported by the ADA and the Calorie Control Council.9,10 Sucralose (Splenda® Original), the most extensively studied of the sweeteners, was supported by 110+ FDA‑reviewed studies and was reaffirmed as safe by a 2026 EFSA re‑evaluation, the most comprehensive assessment of sucralose in over 20 years.1,11
Unlike sugar, Splenda® Sweeteners do not impact blood glucose or insulin levels.
Learn more →In the year‑long SWEET RCT, swapping non‑nutritive sweeteners for sugar helped adults lose and keep off more weight.
Learn more →Splenda® Sweeteners support the low‑sugar lifestyle that GLP‑1 patients need.
Learn more →In the SWEET RCT, non‑nutritive sweeteners led to beneficial shifts in gut microbiome composition, unlike sugar.
Learn more →Stevia grown on a U.S. farm in Florida, with a farm‑to‑table story you can lean into with patients.
Learn more →The sweetener brand recommended most by healthcare professionals clinically treating patients.
Learn more →Broadly available where your patients already shop, making the recommendation easy to act on.
Learn more →Recommend Splenda®, your patient scans a QR code to enroll, and Splenda® delivers product matches, digital coupons, and ongoing support.
No extra work for your practice.
Downloadable handouts, diabetes‑friendly recipes, and patient testimonials to support the low‑sugar conversation.
Browse resources →CE‑oriented webinars and podcasts on sugar reduction, diabetes management, and sweetener science.
Continue learning →Swapping my afternoon soda for a sparkling water with Splenda® was the first change I actually stuck with.
My dietitian gave me the two‑week plan. Cutting back on sugar felt manageable instead of all‑or‑nothing.
I didn’t think I could bake without sugar. The muffin recipe changed my mind, and my A1C conversation.
Illustrative testimonials for prototype purposes. Replace with reviewed, consented patient statements before deployment.
Explore the evidence on the health topics most relevant to your patients, from sugar reduction and blood glucose to weight management, safety, and emerging areas of research. For quick talking points, see Explore the Benefits; for patient objections, see Common Questions.
RCTs and meta‑analyses consistently confirm no clinically significant effect for sucralose, stevia, and monk fruit versus placebo.
Explore the evidence →In the year‑long SWEET RCT, swapping non‑nutritive sweeteners for sugar helped adults lose and keep off more weight.
Explore the evidence →Why replacing added sugar matters, and how the comparison to sugar (not water) frames the benefit.
Explore the evidence →Decades of regulatory review, established ADIs, and how real‑world intake compares. Includes regulatory status.
See the ADI tool →In the SWEET RCT, non‑nutritive sweeteners led to beneficial shifts in gut microbiome composition, unlike sugar.
Explore the evidence →In a carefully controlled RCT, compared to sugar, non‑nutritive sweeteners led to significant decreases in BMI, total cholesterol, and LDL‑C.
Explore the evidence →These are marketing terms, not safety categories. Regulators assess additives on data, not origin, with real‑world intake well below the ADI.
Explore the evidence →No regulatory body has found Splenda® Sweeteners to be associated with increased cancer risk, and they do not show a genotoxicity signal.
Explore the evidence →The domain‑by‑domain evidence summary across glycemic, microbiome, and safety endpoints.
Explore the evidence →The quick case for each benefit: what Splenda® offers and what it means for your patients. For the referenced detail, follow any benefit into Clinical Evidence. For patient objections, see Common Questions.
Unlike sugar, Splenda® Sweeteners do not impact blood glucose or insulin levels.
RCTs and meta‑analyses consistently confirm no clinically significant effect for sucralose, stevia, and monk fruit versus placebo.
For patients managing blood glucose, substituting Splenda® for sugar supports time‑in‑range goals.
Swapping in Splenda® Sweeteners helps patients cut calories and keep weight off.
In the year‑long SWEET RCT, adults who swapped in non‑nutritive sweeteners for sugar lost and kept off significantly more weight than those who continued to consume sugar.
Less sugar, fewer calories with Splenda® Sweeteners.
Splenda® Sweeteners support the low‑sugar lifestyle that GLP‑1 patients need.
Splenda® Sweeteners cut sugar and calories, supporting the nutrient‑rich diets that GLP‑1 patients need; they help make hydration goals easier to obtain and protein shakes taste great.
Splenda® supports GLP‑1 treatment; cutting unnecessary calories leaves room for nutrient‑dense options.
Splenda® offers gut‑friendly sweeteners patients can feel good about.
In the SWEET RCT, participants in the non‑nutritive sweetener group experienced beneficial shifts in their microbiome that are associated with enhanced metabolism and better appetite control, both of which contribute to weight loss maintenance.
For patients weighing sugar versus a Splenda® alternative, these shifts support metabolism and appetite control.
Stevia grown on a U.S. farm in Florida, with a farm‑to‑table story and a "how it is made" narrative you can lean into with patients who value it.
An option that connects a familiar brand to domestic sourcing patients can feel good about.
The Splenda® brand family is the sweetener brand recommended most by healthcare professionals clinically treating patients, a recognized name HCPs and patients already know, which lowers the barrier to acting on a recommendation.
A recommendation carries weight when it comes with a brand patients recognize and can find easily.
Broad availability where your patients already shop, so a recommendation is easy to act on.
Fewer barriers between your recommendation and the patient making the swap.
Confident responses to the questions and misinformation HCPs hear most. Each answer links to the underlying Clinical Evidence.
Most questions come from misleading coverage of single studies. A few things help put that coverage in context:
The objection is usually about non‑nutritive sweeteners as a category. The confident response is about Splenda®. Each answer includes what you can tell your patient, and links to the underlying evidence.
This was not a safety warning. WHO’s 2023 guideline was a conditional, low‑certainty comment on weight control that excludes diabetics.
“The WHO note was about weight control, not safety, and it does not apply if you have diabetes.”
Yes. For a patient choosing something sweet, replacing sugar with non‑nutritive sweeteners can help avoid spikes in blood glucose in those with type 2 diabetes, and cut calories and added sugar for those managing their weight.
“If you are going to have something sweet, these are a better choice than sugar.”
No. The evidence does not show increased appetite or compensatory eating that outweighs the calorie savings versus sugar.
“Swapping sugar for these will not make you crave more; the studies do not show that.”
No. Human RCTs do not show harm to the microbiome at typical intakes; some data demonstrate a benefit.
“At the amounts people actually use, the human studies do not show harm to your gut.”
No. Safety is judged on data, not origin. Sucralose has a well‑established safety profile backed by both FDA and EFSA review.
“Artificial does not mean unsafe. These are judged on the data and are very well studied.”
No. No regulatory authority classifies Splenda® Sweeteners as carcinogenic or genotoxic.
“No health authority classifies these as something that causes cancer or damages DNA.”
No. Dextrose and maltodextrin carriers are present in some sweeteners, but the amount is small, and there is no type 2 diabetes‑related clinical evidence at these doses.
“The small amount of carrier in some packets will not meaningfully affect your blood sugar.”
No. Splenda® Sweeteners have no significant effect on blood glucose or insulin.
“These sweeteners do not raise your blood sugar the way sugar does.”
Typical use is well within the established acceptable daily intakes.
“Everyday use is far below the safety limits regulators set.”
Patient handouts and recipes, professional education, and the Splenda® Sweet Swap program, all in one place.
How to spot added sugars on a Nutrition Facts label, and why they matter for blood glucose.
Download →Simple, realistic substitutions patients can make in coffee, baking, and snacks.
Download →A plain‑language guide to carbohydrates, total sugars, and added sugars.
Download →What non‑nutritive sweeteners are, how they differ, and what the evidence says, written for patients.
Download →A printable shopping checklist organized by aisle to make lower‑sugar choices easier.
Download →A gentle 14‑day starter plan patients can follow after your recommendation.
Download →View recipe →
View recipe →
View recipe →
View recipe →
Browse the full diabetes‑friendly recipe collection on splenda.com.
Referenced summaries by topic, drawn from the full evidence base.
Go to Clinical Evidence →Recorded and upcoming sessions on the evidence, the 2026 EFSA re‑evaluation, and counseling strategy.
View webinars →A "what I tell my patient" guide keyed to Common Questions. Content to be developed.
Download guide →Help patients match the right Splenda® product to their needs. Tool to be built.
Open product finder →Recommend once, and Splenda® Sweet Swap supports your patients with samples, savings, and sugar‑reduction guidance. No forms to manage afterward.
Register your practice once to opt in. It takes a minute and there is nothing to manage afterward.
You receive patient‑facing QR cards and samples to hand out during a low‑sugar conversation.
Patients scan their card to enroll and receive product matches, savings, and ongoing guidance.
Opt in on the Splenda® Professionals site to get free samples and patient‑facing Sweet Swap materials for your office. No forms to manage afterward.
Sign up for free resources →Healthcare professional sign‑up · splenda.com/professionals
After you sign up, we provide pre‑printed patient QR cards and samples to hand out in your office. Patients scan their card to enroll, so the enrollment link is not posted publicly.
A continually updated summary of the evidence for sucralose and non‑nutritive sweeteners (NNS).
Covers carcinogenicity, glycemic effects, the microbiome, regulatory status, and established ADIs, with full citations.
Prefer to read by topic? Each of the clinical questions is available as its own referenced page with a downloadable one‑pager.
Regulators set intake limits with a large safety buffer, well above what people consume.
Highest experimental dose free from any adverse effect.
Scales with body weight.1
NOAEL divided by a 100‑fold safety factor.
Sucralose ADI: 5‑15 mg/kg BW/day.2,3,4
Estimated real‑world intake, a measured population average well below the ADI.5,6 Ten packets a day is on the high end of typical use.
The ADI is a conservative measurement: it is the NOAEL reduced by a large safety factor.
The NOAEL is the highest experimental dose that produces no adverse effect at all.1
Dividing the NOAEL by 100 yields the ADI, the amount safe to consume every day. For sucralose: 5‑15 mg/kg BW/day.2,3,4
The EDI is estimated from actual consumption and compared to the ADI. For sucralose it sits well below the limit.5,7,6
Real‑world consumption of sucralose and other non‑nutritive sweeteners is well below established safety levels in the US and globally.5,7,6
Every source cited across this site, listed alphabetically.
For healthcare professionals only. Illustrative prototype; not for external use without medical, regulatory, and legal review.